Activation of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor pathway is a promising therapeutic strategy to selectively eradicate cancer cells, including non-small cell lung cancer (NSCLC) cells.
Introduction
The basic apoptotic machinery can be activated through two distinct pathways.
The mitochondrial or so-called "intrinsic" apoptotic pathway involves mitochondrial outer membrane permeabilization (MOMP), regulated by the Bcl-2 family of proteins, and subsequent release of pro-apoptotic factors, e.g.
cytochrome-c and Smac/ DIABLO, formation of the apoptosome and activation of initiator caspase-9 [Green and Reed, 1998; Cain et al., 1999] . The death receptor (DR) pathway, or "extrinsic" apoptotic pathway, is triggered by membrane-bound death receptors, which, after binding to their ligands, recruit several intracellular proteins to their cytosolic domain, forming the "deathinducing signalling complex" (DISC), responsible for activating initiator caspase-8 [Wallach et al., 1999] .
The tumor necrosis factor (TNF) family consists of proteins involved in proliferation, differentiation and apoptosis [Krammer, 1998 ]. Examples of members of this family are TNF-Į, CD95L and TNF-related apoptosis-inducing ligand (TRAIL, also known as Apo-2L) [Suliman et al., 2001] . Contrary to other TNF family members, TRAIL is expressed in a broad range of tissues and exerts great antitumor activity, selectively inducing apoptosis in tumor cells, sparing normal cells [MacFarlane, 2003; Wang and El-Deiry, 2003 ]. Systemic administration of TRAIL reduced mammary adenocarcinoma growth in mice without any of the toxic effects, notably no hepatotoxicity, observed when using FasL or TNF-Į [Suliman et al., 2001] . Therefore, TRAIL might constitute a promising anti-cancer agent and currently clinical studies are being conducted with rhTRAIL as well as agonistic monoclonal antibodies directed against the TRAIL-R1 and -R2 receptors [Tolcher et al., 2004; Ling et al., 2006; Patnaik et al., 2006] . TRAIL can bind to five receptors, of which four are located at the cell surface:
TRAIL-R1 (DR4), TRAIL-R2 (DR5/ KILLER), TRAIL-R3 (DcR1) and TRAIL-R4 (DcR2) [Wang and El-Deiry, 2003] . Besides the TNF homology domain (THD), they possess the TRAIL-binding site (TBS). When a specific TRAIL-receptor trimerizes, it can bind via the TBS to the TRAIL ligand [Bodmer et al., 2002] . A soluble receptor called osteoprotegerin (OPG) can also bind TRAIL but with lower affinity [Wang and El-Deiry, 2003 ]. Only two of these receptors, R1 and R2, contain a functional cytoplasmatic death domain (DD) motif and are capable of delivering TRAIL's apoptotic signal by association of the DD with the FAS-associated death domain (FADD) protein, containing the death effector domain (DED), which is involved in the activation of caspase-8 [Suliman et al., 2001] . TRAIL can bind with similar affinity to R1 and R2 [Schneider et al., 1997] . The other two receptors, DcR1 and DcR2, are called "decoy receptors", lacking the ability to initiate the apoptotic cascade. DcR2 contains a truncated DD while the DD of DcR1 lacks a cytoplasmatic domain [Wang and El-Deiry, 2003 ].
A correlation between TRAIL sensitivity and DR4, DR5 and/ or decoy receptor expression has been claimed in some cell lines [Georgakis et al., 2005; Khanbolooki et al., 2006] . For example, normal cells were reported to express high levels of DcR receptors and low levels of the R1 receptor [Kim et al, 2000] . It was shown that removal of surface DcR1 by phosphatidylinositolspecific phospholipase-C could overcome resistance to TRAIL-induced apoptosis [Zhang et al., 2000] . However, others claimed expression of decoy receptors does not explain TRAIL resistance [Griffitih et al., 1999] .
Furthermore, DcR2 might rather be a regulatory receptor instead of a decoy receptor. Whereas most TNF receptors normally form only homotrimeric complexes, preligand assembly domains in TRAIL-R2 and TRAIL-R4 permit mixed complex formation, thus regulating apoptosis induction, without the requirement of ligand binding by DcR2 [Clancy et al., 2005] .
Different studies relate resistance to TRAIL-induced cell death to downstream factors. It has been shown that down-regulation of cellular FLICE-like inhibitory protein (c-FLIP) can sensitize cells to TRAIL-induced apoptosis [Siegmund et al., 2002; Okano et al., 2003 ]. Overexpression of Bcl-2 was related with inhibition of TRAIL-induced apoptosis [Fulda et al, 2002; Abou El Hassan et al, 2004] . Also, it has been shown that resistant cells can become sensitive when treated with chemotherapeutic agents [Griffitih et al., 1999] .
Recently, reports show a sensitization to TRAIL-induced apoptosis in a variety of tumor cell types by combining TRAIL with proteasome inhibitors, e.g. bortezomib (Velcade) [Johnson et al., 2003; Zheng et al., 2004; Georgakis et al., 2005; Khanbolooki et al., 2006] . The mechanism of sensitization seems to differ among cell types but typically involves increased caspase-8 activation with or without a decrease in the level of c-FLIP. Furthermore, a bortezomibinduced increase in the levels of BH3-only pro-apoptotic Bcl-2 proteins such as Bik and Bim, as well as inhibition of (TRAIL-induced-)NF-NB activation may play a role [Keane et al., 2000; Johnson et al 2003; Sayers et al., 2005; Nikrad et al., 2005; Khanbolooki et al., 2006] .
In this study, we evaluated susceptibility to TRAIL therapy in NSCLC cells and analyzed the expression of the different TRAIL receptors. We observed synergistic apoptosis induction when rhTRAIL was combined with proteasome inhibitor bortezomib. Molecular events underlying this synergistic apoptosis induction were investigated.
Materials and methods

Cell Lines and Drugs
NSCLC cell lines H460, A549, SW1573, H292, H1299 and H322 were obtained from the American Type Culture Collection (ATCC) (Manassas, VA). We have previously generated stably transfected derivatives of H460 cells, overexpressing Bcl-2 (H460-Bcl-2) and caspase-8 inhibitor CrmA (H460-CrmA) [Ferreira et al, 2000] . SW1573 cells were cultured in DMEM tissue culture medium (Cambrex Bioscience, Verviers, Belgium). H460, A549, H292, H1299 and H322 cells were cultured in RPMI 1640 medium (Cambrex Bioscience). Culture mediums were supplemented with (v/v) 10% FCS, 100 units/ ml penicillin, and 100 ǋg/ml streptomycin (Invitrogen, Breda, The Netherlands). Cells were grown at 37°C in a humidified atmosphere containing 5% CO 2 . The replication incompetent adenovirus-encoding TRAIL (AdTRAIL) was constructed as described before 
Growth-Inhibition Assay
The cytotoxic effect of TRAIL-receptor-directed monoclonal antibodies (mAbs), AdTRAIL, rhTRAIL, and of bortezomib in combination with rhTRAIL or AdTRAIL, was determined by incubating cells at a density of 1x10 3 per well of 96-well flat-bottomed plates (Costar, Corning, NY) 24h prior to treatment. In AdTRAIL studies, cells were incubated with different multiplicity of infection (MOI) i.e., virus to cell ratios of AdTRAIL (range: 0-200).
The infection procedure was as described before [Abou El Hassan et al, 2004] . Cells were incubated with 50 μl/well of different MOIs at 37 ºC. Two hours after infection, the same volume of virus-free medium was added to each well. In the TRAIL-R1/2 mAb and rhTRAIL studies, cells were incubated with 100μl/well of antibodies (range: 0-30 μg/ml) or rhTRAIL (range: 9.4-300 ng/ml). For the combination studies with bortezomib, a fixed dose of TRAIL (50 ng/ml) was combined with a concentration range of bortezomib (3-500 nM 
Measurement of mRNA Transcript Levels of TRAIL receptors
Total RNA was isolated from the human cell lines with TRIzol reagent (Invitrogen) according to the manufacturer´s instructions. RNA samples (5μg) were treated using a DNA-free RNA kit (Zymo Research, Orange, CA). cDNA synthesis was performed using a RNA PCR kit containing an oligo(dT) 20 primer (Invitrogen). Reverse transcription was performed using a thermal program of 50ºC for 60 min and 85ºC for 5 min. PCR reactions were performed using the primers published by Griffith et al., 1998 [Griffith et al, 1998 ]:(TRAIL-R1 ( Samples were resolved on a 1% agarose gel and visualized with ethidium bromide.
Measurement of Surface Expression of TRAIL-receptors
Five million cells, untreated or treated with bortezomib (100nM for 16h) (H460 cells only)
were added to a FACS tube and stained with receptor-specific mAbs for 1 hour at 4º C.
To control for non-specific binding, an IgG1 antibody (DAKO) for R1 and R4 and an 
Cell Death Measurement
Propidium iodide (PI) staining and flow cytometry analysis were performed as described previously [Ferreira et al., 2000] . The fraction of cells with hypodiploid (sub-G 1 ) DNA content, was taken as the apoptotic cell population. The percentage of apoptosis indicated was corrected for background sub-G 1 levels found in the corresponding untreated controls.
Western blot analysis
Western blot analysis was performed as described before [Ferreira et al., 2000] . Rabbit polyclonal primary antibodies used were: anti-caspase-9, anti-caspase-3, anti-PARP, 
NF-ǉB activity luciferase assay
The NF-ǉB reporter construct (pNF-ǉB) (Clontech, Mountain View, CA) containing the firefly luciferase (luc) gene from Photinus pyralis and four tandem copies of the NF-ǉB consensus sequence fused to a TATA-like promoter (P TAL ) region from the Herpes simplex virus thymidine kinase (HSV-TK) promoter was used. After endogenous NF-ǉB proteins bind to the kappa (N) enhancer element, transcription is induced and the reporter gene is activated. Fifteen thousand H460 cells were plated in each well of 96-well flat-bottomed plates and incubated until 60-80% confluency. Cells were co-transfected with pNF-ǉB (1.0 Pg/ml) and, for normalization, pRL-CMV (0.1 Pg/ml) (Promega, Madison, WI) using the SuperFect transfection reagent (QIAGEN, Venlo, The Netherlands). Following transfection, cells were cultured with either bortezomib (100 nM), rhTRAIL (50ng/ml), alone or in combinations for 13h, at which time luciferase activity was measured.
Luciferase activities in cell lysates were measured using the Dual Luciferase assay system (Promega) and a Luminat LB9507 luminometer (EG&G Gerthold, Bad Wildbad, Germany). Results were expressed as relative light units (RLU) normalized for Renilla luciferase activity. The results are presented as the fold induction, which is the relative luciferase activity of the treated cells over that of control cells. All transfection experiments were carried out in triplicate wells and repeated separately at least three times.
Results
The cytotoxic effects of TRAIL therapy in NSCLC cells
A commonly used strategy to activate the TRAIL-receptor pathway is exposing Here we studied alternative, potentially more effective, strategies to activate TRAIL-receptor mediated apoptosis. Figure 1A shows the growth curves of NSCLC cells treated with TRAIL-R1-and -R2 directed monoclonal antibodies.
Antibodies have higher binding affinity and less reactivity towards decoy receptors, which can lead to an altered cytotoxicity profile compared to rhTRAIL [Finnberg et al, 2006] . The IC 50 values for each antibody were determined ( Figure 1C ) showing no differential sensitivity to either antibody.
We then asked the question whether the relative resistance of some NSCLC cell lines, e.g. A549 and SW1573, to the antibodies could be referred to the sole activation of one death receptor instead of dual receptor activation and therefore cells were infected with a full-length TRAIL-encoding adenovirus.
Full-length TRAIL has been reported to induce a media-transferable bystander effect and was shown to induce apoptosis in rhTRAIL-resistant cell lines, including NSCLC cell lines [Voelkel-Johnson et al., 2002; Seol et al., 2003] . Figure 1B shows the growth curves for NSCLC cells infected with AdTRAIL. IC 50 values corresponding to the multiplicity of infection (MOI) of AdTRAIL necessary to kill 50% of the cells were calculated ( Figure 1C) . The comparative sensitivity of the tested cell lines to the full-length TRAIL was comparable to the antibodies and the viability of the A549 and SW1573 cells was hardly affected. Next, we examined whether H460 and SW1573 cells displayed a similar differential sensitivity when exposed to soluble rhTRAIL.
Indeed, H460 cells were more sensitive than SW1573 cells to both the growth inhibitory and apoptosis-inducing effects of rhTRAIL ( Figure 1D ). 
Combination therapy with the proteasome inhibitor Bortezomib
To evaluate whether co-incubation with proteasome inhibitor bortezomib can sensitize NSCLC to rhTRAIL-induced apoptosis, sensitive H460 and resistant SW1573 cells were exposed for 24h to various concentrations of bortezomib (3-500nM) in presence or absence of a fixed concentration of rhTRAIL (50ng/ ml). Furthermore, as a control, samples were treated with rhTRAIL (50ng/ ml) only. Figure 3A shows the growth curves for the two cell lines treated with bortezomib or bortezomib and rhTRAIL. We then determined the "predicted" growth inhibition curve of the combination of the two drugs by fractional effect analysis . The predicted growth inhibition curve indicates the curve obtained in case of additive growth inhibition by combining bortezomib and rhTRAIL. At each concentration of bortezomib the relative growth inhibitory effect of treatment with only TRAIL (50ng/ ml) was multiplied with the relative effect of treatment with only bortezomib ]. An actual growth inhibition curve inferior to the predicted curve indicates synergistic growth inhibition.
We observed synergistic growth inhibition at 50 nM or higher concentrations of bortezomib combined with TRAIL (50ng/ ml). This may be related to the level of proteasome activity inhibited. Previously we showed the proteasome activity to be reduced to 25% of its basal level when H460 cells were treated with 100nM bortezomib.
However, the proteasome activity was not significantly inhibited when cells were treated with only 10nM [Voortman et al, 2007] . Also, in a proof of principle experiment, the growth inhibitory effect of combining AdTRAIL (MOI 10) and a concentration range of bortezomib in H460 cells was examined,
showing a similar synergistic activity at higher bortezomib concentrations ( Figure 3B ). Figures 3C-D show the apoptosis-inducing activity of bortezomib and rhTRAIL alone, or upon simultaneous exposure in NSCLC cells. Figure 3C shows in H460 cells that the simultaneous treatment of bortezomib and rhTRAIL results in a synergistic increase of the apoptotic subG 1 population, as reported to increase caspase-8 activation in rhTRAIL-exposed human bladder and prostate cells via a p21-dependent mechanism we evaluated if bortezomib induces p21 in H460 cells [Lashinger et al., 2005] . As shown in figure 4D , p21, as well as p53, is stabilized upon bortezomib treatment, which may also in these NSCLC cells contribute to the observed increased caspase-8 activation upon combination treatment with bortezomib and rhTRAIL.
Additionally it was shown that bortezomib is more potent than rhTRAIL in inducing cleavage of caspase-9. Combining both drugs, enhanced caspase-9
cleavage and diminishing of pro-caspase-9 was observed, resulting in p35 and p37 fragments. Enhanced processing of caspase-9 coincided with rhTRAILinduced Bid cleavage and bortezomib-induced accumulation of proapoptotic BH3-only protein Noxa. The level of X-linked Inhibitor of Apoptosis (XIAP), a known inhibitor of caspase-3 and caspase-9, was not affected by treatment with bortezomib ( Figure 4D ). Taken together, the synergistic activity between bortezomib and rhTRAIL occurs both at the level of caspase-8 activation and mitochondria-dependent caspase-9 activation, resulting in enhanced effectorcaspase-3 processing and PARP cleavage. A, measurement by PI-staining-based FACS analysis of the subG 1 fraction of H460 cells and H460 cells stably overexpressing Bcl-2 (H460-Bcl-2) or CrmA (H460-CrmA), upon exposure to bortezomib (100nM), rhTRAIL (50ng/ml) or the combination of both drugs, for 24h. B, PI-staining profiles and subG 1 fractions (% of total population indicated r SD) are shown for H460 cells pre-treated with the pancaspase inhibitor zVAD-fmk for 2h and subsequently treated with either rhTRAIL (50ng/ml), bortezomib (100nM), or the combination of both drugs. Means of triplicate determinations r SD. C, expression levels of caspases 8, 9 and 3, as well as PARP, Bid, c-FLIP and NOXA were determined by Western blot analysis of total cell extracts of H460 cells treated with rhTRAIL (50ng/ml), bortezomib (btz) (100nM), or the combination of both drugs, for 24h (*: aspecific band). D, expression levels of p53, p21 and XIAP determined by Western blot analysis, in total cell extracts of H460 cells treated with bortezomib 100nM for various periods of time.
Bortezomib induces increased surface expression of death receptors and inhibits rhTRAIL-induced NF-ǉB activation
We next evaluated if treatment with bortezomib induced the surface expression of the death receptors, to provide a possible mechanism for the enhanced caspase-8 processing in the combination with rhTRAIL. As shown in Figure 5A -B, upon treatment with bortezomib levels of both receptors were increased. This effect was superior for the TRAIL-R2 receptor compared to the TRAIL-R1 receptor. Exposure to bortezomib exceeding 16 hours did not lead to a significant further increase in the level of surface expression of both death receptors (data not shown). Furthermore, rhTRAIL was examined for NF-NB activation potential and the inhibitory effect of bortezomib on NF-NB activation was determined in H460 cells transfected with the NF-NB luciferase reporter construct. and TRAIL-R2 in untreated (UT) H460 cells and upon 16 hours of exposure to bortezomib (100nM), analyzed by FACS using TRAIL-R1 and -R2 antibodies. Isotype-matched antibodies were used to control for unspecific binding. B, relative surface expression levels of TRAIL-R1 and TRAIL-R2 compared to the negative control (set at 1.0) in untreated H460 cells and H460 cells treated for 16h with bortezomib 100nM. C, effect of rhTRAIL on NF-ǉB reporter activity in H460 cells. H460 cells were transfected with an NF-ǉB luciferase plasmid. Transfected cells were cultured with either TRAIL (50 ng/ml), bortezomib (100nM), or in combinations, for 13 hours, at which time luciferase activity was measured. D, PI staining profile and the subG 1 fraction (% of total population indicated r SD) of H460 cells treated with Helenalin (10uM), TRAIL (50 ng/ml), or the combination. Means of triplicate determinations r SD.
Upon treatment with rhTRAIL we observed an approximately 2.5-fold increase in NF-NB activity, which could be effectively reduced to the constitutive level by co-incubation with bortezomib ( Figure 5C ). These findings thus indicate that part of the apoptosis promoting effects of bortezomib is mediated by inhibition of TRAIL-induced NF-NB activation. Indeed, simultaneous exposure to rhTRAIL (50ng/ml) and Helenalin (10PM), a specific inhibitor of NF-ǉB, which irreversibly alkylates the p65, resulted in enhanced apoptosis induction compared to rhTRAIL or Helenalin treatment alone ( Figure 5D ). Nevertheless, apoptosis induction by this combination was significantly less compared to the combination of rhTRAIL and bortezomib, 2.5-fold compared to 4-fold, respectively (see also Figure 3C ). As a positive control we tested the effect of bortezomib and Helenalin against TNF-D-induced NF-NB activation, showing comparable capacity at the tested concentrations to inhibit NF-ǉB activity (data not shown).
Discussion
In the first part of this study we evaluated the cytotoxic effects of TRAIL therapy in NSCLC cells. H460, H292 and H1299 cells were more sensitive to TRAIL-R1 or -R2 antibody-induced growth inhibition than A549 and SW1573 cells. We observed a similar sensitivity profile using AdTRAIL or rhTRAIL. This suggests that activation of either one of the TRAIL receptors is sufficient for the full activation of the apoptotic machinery of the cell.
Increased surface expression of DR4 and DR5 has been associated with TRAILsensitivity in for example pancreatic cancer cells, however was not a determinant for TRAIL-sensitivity in lymphoma cells [Georgakis et al., 2005; Khanbolooki et al., 2006] . In NSCLC cells, sensitivity to TRAIL therapy was not associated with the expression levels of the different TRAIL receptors.
TRAIL-receptor mRNA transcript levels were comparable among cell lines.
Sensitivity could also not be related to the surface expression levels of the receptors. Cells with similar expression levels of TRAIL R1 and R2, e.g. H1299,
H292 and SW1573 cells, can either be sensitive or resistant to TRAIL-induced cytotoxicity. Furthermore, the RT-PCR results show higher transcript levels for R1 than R2 in A549 cells but FACS analysis of surface expressed receptors revealed a higher expression of R2 in the cell surface, indicating no direct correlation between transcript and protein levels. This may be caused by a deficient transport of the TRAIL-receptor to the cell surface, as was recently demonstrated for R1 [Ferreira et al., 2000; Jin et al., 2004] .
Alternative mechanisms of resistance could be related to genetic alterations, which are rare and therefore not examined. For example, no mutations in TRAIL-receptors were found in a study evaluating 100 primary NSCLC tumors from white American patients [Wu et al., 2000] . Furthermore, there is also little evidence supporting a high degree of epigenetic silencing by overmethylation of the TRAIL-R1 and TRAIL-R2 receptors in NSCLC.
Nevertheless, a 31% rate of aberrant methylation of the so-called decoy receptors, DcR1 or DcR2 was shown [Shivapurkar et al., 2004] . According to our results the NSCLC cell lines studied do not express decoy receptors DcR1
and DcR2 on the cell surface, even though, for the DcR2 receptor, high mRNA transcription levels were detectable in H292, A549 and SW1573 cells. Lacking surface expression of these receptors might contribute to their susceptibility to TRAIL-induced apoptosis compared to normal cells [Kim et al., 2000] .
Together, it appears that signalling downstream of receptor activation is the major determinant of sensitivity. This notion is also emphasized by our results This was further indicated by the fact that overexpression of caspase-8
inhibitor CrmA completely abrogated synergistic apoptosis induction. In agreement with our findings, bortezomib has been shown to prevent the degradation of TRAIL-R1 and -R2 in other tumor cell types as well [Johnson et al, 2003] . In contrast to other tumor types, we did not observe a bortezomibinduced decrease in the expression level of caspase-8 inhibitor c-FLIP in H460
NSCLC cells [Conticello et al., 2007] . Others equally showed stabilisation of c-FLIP in A549 cells upon treatment with proteasome inhibitor MG132 [Liu et al, 2006] . apoptosis through the death receptor mediated route, including activation of initiator caspase 8 and effector caspase 3, Bid cleavage and subsequent low level activation of caspase 9 ("amplification loop"). TRAIL-induced NF-ǉB activation suppresses apoptosis. B, bortezomib-induced apoptosis through the mitochondria mediated route, including modulation of the balance between Bcl-2 family proteins towards apoptosis (including accumulation of NOXA, Bik and Bim), resulting in MOMP, activation of initiator caspase-9 and effector caspase-3. Bortezomib treatment induces surface expression of TRAIL-R1 and -R2. Bortezomib treatment does not significantly inhibit constitutive NF-kB activation ("="). C, synergistic apoptosis activation by combining rhTRAIL and bortezomib results from increased caspase-8 activation, due to increased death receptor surface expression, and increased caspase-9 activation through the amplification loop. Furthermore rhTRAIL-induced NF-NB activation is inhibited by bortezomib co-treatment, resulting in a level equal to untreated cells ("=").
TRAIL-induced apoptosis activation leads to cross-talk between the extrinsic and intrinsic apoptotic pathways via Bid cleavage [Hengartner 2000; Suliman et al., 2001; Abou El Hassan et al., 2004] . This so-called "amplification loop" encompasses activation of the intrinsic or mitochondrial apoptotic pathway as a result of activation of the extrinsic apoptotic pathway. Though Type 2 cells, treatment with rhTRAIL is likely to result only in a low level of caspase-9 activation, as caspase-9 processing upon rhTRAIL treatment was limited.
Others equally showed in NSCLC cells that apoptosis-induction by various TRAIL preparations could only be marginally inhibited by a caspase-9 inhibitor [Kim et al., 2004] . Interestingly, we observed a sensitization to rhTRAILinduced caspase-9 processing, as caspase-9 processing was superior when the two drugs were combined compared to either treatment alone. This likely results from a combined modulation towards apoptosis of Bcl-2 family members, favoring MOMP and apoptosome mediated caspase-9 processing/ activation. To this effect we observed rhTRAIL-induced processing of proapoptotic BH3-only protein Bid, activating the amplification route, combined with bortezomib-induced accumulation of proapoptotic BH3-only proteins Bik, Bim, and most importantly Noxa [Voortman et al., 2007] .
Interestingly, it was shown by others as well that when a (proapoptotic) BH3-mimic agent was combined with rhTRAIL, the combination induces a strong enhancement of apoptosis compared to either agent alone [Yeow et al., 2006] . Notably, we observed that rhTRAIL-as well as bortezomib-induced apoptosis can be inhibited by Bcl-2 overexpression. Bcl-2 is typically an inhibitor of mitochondrial apoptosis, but it was also shown previously by us and others that its overexpression is capable of inhibiting AdTRAIL or rhTRAIL-induced caspase-8 activation as well (Fulda et al., 2002; Abou El Hassan et al., 2004] .
Finally, we showed that bortezomib effectively inhibits rhTRAIL-induced NF-ǉB activation, which might also be a contributing factor to TRAIL therapyresistance. It has been previously reported by others as well that inhibition of NF-ǉB activation, e.g. by a p65-specific siRNA construct or an IǉB kinase (IKK) inhibitor, preventing nuclear localization of the p65 subunit of NF-ǉB, could sensitize cancer cells to TRAIL-induced apoptosis [Khanbolooki et al., 2006] . However, in Hodgkin disease cell lines apoptosis induction by bortezomib was independent of inhibitor of NF-kB mutations and synergistic apoptosis induction combining bortezomib with rhTRAIL or agonistic TRAIL-receptor antibodies was hypothesized to result from alternative mechanisms, e.g. downregulation of cFLIP levels [Zheng et al., 2004] .
In conclusion, NSCLC cells are differentially sensitive to TRAIL therapy, with no correlation between sensitivity and expression levels of TRAIL-receptors.
Treatment with bortezomib sensitizes NSCLC cells to rhTRAIL by increased activation of caspase-8 as well as caspase-9 mediated apoptosis implicating both the extrinsic and intrinsic route of apoptosis. Combination treatment of bortezomib and rhTRAIL potentially constitutes a new treatment strategy for non-small cell lung cancer patients.
